Expanded Access Program With Nivolumab Monotherapy in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimens for the Treatment of Stage IIIb/IV SqNSCLC

Trial Profile

Expanded Access Program With Nivolumab Monotherapy in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimens for the Treatment of Stage IIIb/IV SqNSCLC

Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Expanded access; Therapeutic Use
  • Acronyms CheckMatev 169
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 28 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 11 Jan 2016 New indication added: Non-squamous non-small cell lung cancer as per ClinicalTrials.gov record.
    • 25 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top